Abstract：
Squamous cell carcinoma of the external auditory canal (EACSCC) is a rare condition. However, a standard treatment has not yet been established. We retrospectively evaluated the efficacy, adverse events, and feasibility of TPF-CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced EACSCC.
Thirty-five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF-CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a.
Five-year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five-year progression-free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% (p = 0.022), respectively.
TPF-CCRT should be considered as a plausible treatment option for advanced EACSCC.
Thirty-five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF-CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a.
Five-year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five-year progression-free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% (p = 0.022), respectively.
TPF-CCRT should be considered as a plausible treatment option for advanced EACSCC.
摘要：
背景：外耳道鳞状细胞癌（EACSCC）是一种罕见的疾病。然而,尚未建立标准治疗方法。我们回顾性评估疗效，不良事件,TPF-CCRT（多西他赛伴随放化疗，顺铂,和5-氟尿嘧啶）在晚期EACSCC患者中。
方法：纳入神户大学医院最初接受TPF-CCRT治疗的35例晚期EACSCC（T3，T4）患者。T4疾病与大脑的入侵，颈内动脉,或颈内静脉被分类为T4b，没有这些特征的被归类为T4a。
结果：T3和T4的5年总生存率分别为100%和64.2%，分别。T4a和T4b之间存在显着差异（82.4％与30%,p=0.007)。T3，T4a的五年无进展生存率，T4b为100%，68%,和20%(p=0.022)，分别。
结论：TPF-CCRT应被视为晚期EACSCC的合理治疗选择。
方法：纳入神户大学医院最初接受TPF-CCRT治疗的35例晚期EACSCC（T3，T4）患者。T4疾病与大脑的入侵，颈内动脉,或颈内静脉被分类为T4b，没有这些特征的被归类为T4a。
结果：T3和T4的5年总生存率分别为100%和64.2%，分别。T4a和T4b之间存在显着差异（82.4％与30%,p=0.007)。T3，T4a的五年无进展生存率，T4b为100%，68%,和20%(p=0.022)，分别。
结论：TPF-CCRT应被视为晚期EACSCC的合理治疗选择。
